文献
J-GLOBAL ID:201802226817297954
整理番号:18A0090750
オランダにおける慢性心不全と駆出率が低下した患者に対するアンギオテンシン受容体ネプリリシン阻害剤Sacubitril/バルサルタンの費用対効果:以前と現在のオランダの薬剤経済学的ガイドラインの下での国の適応解析【Powered by NICT】
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines
著者 (8件):
Ramos Isaac Corro
(Institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands)
,
Versteegh Matthijs M.
(Institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands)
,
de Boer Rudolf A.
(Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands)
,
Koenders Jolanda M.A.
(Novartis Pharma B.V., Arnhem, the Netherlands)
,
Linssen Gerard C.M.
(Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, the Netherlands)
,
Meeder Joan G.
(Department of Cardiology, VieCuri Medical Centre Noord-Limburg, Venlo, the Netherlands)
,
Rutten-van Molken Maureen P.M.H.
(Institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands)
,
Rutten-van Molken Maureen P.M.H.
(Institute of Health Care Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands)
資料名:
Value in Health
(Value in Health)
巻:
20
号:
10
ページ:
1260-1269
発行年:
2017年
JST資料番号:
W1810A
ISSN:
1098-3015
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)